ArticleHealth science reports2025
Correlation of Lymphocyte-to-C-Reactive Protein Ratio With Erectile Dysfunction Risk in United States Adult Males during 2001-2004: A Cross-Sectional Analysis.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Erectile dysfunction (ED) is a common condition in aging males and may be influenced by systemic inflammation. This study aimed to examine the association between the lymphocyte-to-C-reactive protein ratio (LCR), a novel inflammatory marker, and ED prevalence in the adult population of the United States. Methods: Data were obtained from the 2001-2004 National Health and Nutrition Examination Survey (NHANES). Male participants aged ≥ 20 years with available LCR and ED data were included. Weighted univariate and multivariable logistic regression analyses were performed to assess the association between LCR and ED. Additional analyses included subgroup assessments, interaction testing, and restricted cubic spline modeling to evaluate nonlinearity. Results: A total of 3952 male participants were included, with a mean LCR of 2.52 ± 0.08 and an ED prevalence of 19.47%. Higher LCR quartiles were associated with a lower prevalence of ED. After adjusting for potential confounders, individuals in the highest LCR quartile had a 37% lower risk of ED compared to those in the lowest quartile (OR: 0.63, 95% CI: 0.41-0.95; Conclusions: LCR is a reliable, readily measurable biomarker that is independently associated with reduced ED risk. It may serve as a promising inflammatory marker for identifying individuals at lower risk of ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.